WO2023205463A1 - Heteroaryl compounds for the treatment of pain - Google Patents

Heteroaryl compounds for the treatment of pain Download PDF

Info

Publication number
WO2023205463A1
WO2023205463A1 PCT/US2023/019469 US2023019469W WO2023205463A1 WO 2023205463 A1 WO2023205463 A1 WO 2023205463A1 US 2023019469 W US2023019469 W US 2023019469W WO 2023205463 A1 WO2023205463 A1 WO 2023205463A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pharmaceutically acceptable
pain
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/019469
Other languages
English (en)
French (fr)
Other versions
WO2023205463A8 (en
Inventor
Mark Thomas Miller
Dennis James Hurley
Timothy Donald Neubert
Vijayalaksmi Arumugam
Sara Sabina HADIDA RUAH
Jason Mccartney
Jinglan Zhou
Jaclyn CHAU
Robert Martin DEMORET
Senait G. GHIRMAI
Roman Askatovich VALIULIN
Alexander Frederik KINTZER
David Robert SLOCHOWER
Kathleen Aertgeerts
Elizabeth Mary BECK
James Jun Bon MUI
Miranda Adele WRIGHT
Ronald Marcellus Alphonsus Knegtel
Ewa Iwona CHUDYK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020247039041A priority Critical patent/KR20250005373A/ko
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority to JP2024562079A priority patent/JP2025513455A/ja
Priority to AU2023256603A priority patent/AU2023256603A1/en
Priority to CR20240513A priority patent/CR20240513A/es
Priority to IL316462A priority patent/IL316462A/en
Priority to CN202380047901.3A priority patent/CN119677737A/zh
Priority to EP23724521.2A priority patent/EP4511116A1/en
Priority to PE2024002287A priority patent/PE20251179A1/es
Publication of WO2023205463A1 publication Critical patent/WO2023205463A1/en
Publication of WO2023205463A8 publication Critical patent/WO2023205463A8/en
Priority to DO2024000209A priority patent/DOP2024000209A/es
Priority to MX2024013020A priority patent/MX2024013020A/es
Priority to JOJO/P/2024/0235A priority patent/JOP20240235A1/ar
Anticipated expiration legal-status Critical
Priority to CONC2024/0015820A priority patent/CO2024015820A2/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • a “C 1 -C 6 alkoxy” group is a radical of the formula -OR a where R a is an alkyl group having the between one and six carbon atoms.
  • the term “haloalkoxy” refers to an alkoxy group having the specified number of carbon atoms, wherein one or more of the hydrogen atoms of the of the alkyl group are replaced by halo groups.
  • the term “alkylene” refers to a divalent, straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing no unsaturation, and having the specified number of carbon atoms, which is attached to the rest of the molecule by two single bonds.
  • stereochemical designators associated with the stereocenters of known absolute configuration are marked with an asterisk (*), e.g., (R*)- and (S*)-, while the stereochemical designators associated with stereocenters of unknown absolute configuration are not so marked.
  • the unmarked stereochemical designators associated with the stereocenters of unknown absolute configuration reflect the relative stereochemistry of those stereocenters with respect to other stereocenters of unknown absolute configuration, but do not necessarily reflect the relative stereochemistry with respect to the stereocenters of known absolute configuration.
  • the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of abdominoplasty pain.
  • the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity in a subject of visceral pain.
  • the visceral pain comprises visceral pain from abdominoplasty.
  • the invention provides the use of a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for the manufacture of a medicament for use in treating or lessening the severity of acute pain, sub-acute and chronic pain, nociceptive pain, neuropathic pain, inflammatory pain, nociplastic pain, arthritis, migraine, cluster headaches, tension headaches, and all other forms of headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy, epilepsy conditions, neurodegenerative disorders, psychiatric disorders, anxiety, depression, bipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, central neuropathic pain of multiple sclerosis and irritable bowel syndrome, incontinence, pathological cough, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, unspecific chronic back pain, head pain
  • doxazosin tamsulosin, clonidine, guanfacine, dexmedetomidine, modafinil, or 4-amino-6,7-dimethoxy-2-(5-methane-sulfonamido-l, 2,3,4- tetrahydroisoquinolin-2-yl)-5-(2-pyridyl) quinazoline;
  • a tricyclic antidepressant e.g. desipramine, imipramine, amitriptyline or nortriptyline
  • an anticonvulsant e.g.
  • the invention in another aspect, includes a composition for coating an implantable device comprising a compound or salt of the invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • the invention includes an implantable device coated with a composition comprising a compound or salt of the invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121.
  • Step 2 8-benzyloxy-6-chloro-1,5-naphthyridine-2-carbonitrile
  • 8-Benzyloxy-6-chloro-1,5-naphthyridine-2-carbonitrile was prepared from 8-benzyloxy- 6-chloro-1-oxido-1,5-naphthyridin-1-ium using a procedure analogous to that found in Intermediate A - 4, step 3.
  • the reaction mixture was cooled to room temperature and partitioned between water (100 mL) and MTBE (500 mL).
  • the biphasic mixture was filtered through Celite® and the layers were separated.
  • the organic layer was washed with water (4x) and brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
  • the residue was adsorbed on silica gel under vacuum and purified by silica chromatography (120 g silica, 0-10% ethyl acetate/heptane) to provide 1.4 g of material.
  • Step 7 2-[4-tert-butyl-2-(4-fluoro-2-methoxy-phenoxy)-6-methyl-phenyl]-4,4,5,5- tetramethyl-1,3,2-dioxaborolane [00415] n-BuLi (1.2 mL of 2.5 M, 3.0 mmol) was slowly added to a solution of 2-bromo-5-tert- butyl-1-(4-fluoro-2-methoxy-phenoxy)-3-methyl-benzene (1.0 g, 2.7 mmol) in THF (20 mL) at -78 °C.
  • Step 1 3-bromo-2-(3,4-difluoro-2-methyl-phenoxy)-4-methyl-5- (trifluoromethyl)pyridine
  • Step 2 A mixture of 3-bromo-2-chloro-4-methyl-5-(trifluoromethyl)pyridine (2.63 g, 9.58 mmol) and 3,4-difluoro-2-methyl-phenol (2.6 g, 18 mmol) was dissolved in DMSO (26 mL). To this solution was added cesium carbonate (7.73 g, 23.7 mmol) and the mixture stirred at 90 °C for 2.5 h. The mixture was allowed to cool to room temperature then diluted with ethyl acetate.
  • the material was purified by reverse phase chromatography (C18, 5-95% acetonitrile/water containing 0.1 % formic acid) and the product-containing fractions concentrated to remove the acetonitrile.
  • the resulting aqueous solution was extracted with ethyl acetate (3 x 100 mL).
  • the combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to provide [2-(3,4-difluoro-2-methyl-phenoxy)-4- methyl-5-(trifluoromethyl)-3-pyridyl]boronic acid (1.64 g, 90%) as a white solid.
  • Step 3 3-bromo-6-methyl-5-(trifluoromethyl)pyridin-2-ol
  • 3-Bromo-6-methyl-5-(trifluoromethyl)pyridin-2-ol was prepared from 6-methyl-5- (trifluoromethyl)pyridin-2-ol using a procedure analogous to that found in Intermediate B - 7, step 2.
  • ESI- MS m/z calc.254.95, found 255.79 (M+1) + .
  • 1 H NMR 400 MHz, DMSO-d 6 ) ⁇ 12.66 (s, 1H), 7.99 (s, 1H), 2.33-2.25 (m, 3H).
  • Step 4 2-(3,4-difluoro-2-methyl-phenoxy)-5-methyl-6-(trifluoromethyl)pyridine-3- carboxylic acid
  • methyl 2-(3,4-difluoro-2-methyl-phenoxy)-5-methyl-6- (trifluoromethyl)pyridine-3-carboxylate (30 g, 78.5 mmol) in methanol (60 mL), THF (120 mL), and water (60 mL) was added lithium hydroxide monohydrate (6.5 g, 155 mmol). The mixture was stirred at room temperature for 2 h and then the volatiles were removed under reduced pressure. The residue was acidified ( ⁇ pH 6) using 2 M HCl.
  • Step 7 5-chloro-2-(3,4-difluoro-2-methyl-phenoxy)-6-(trifluoromethyl)pyridin-3-amine
  • 5-Chloro-2-(3,4-difluoro-2-methyl-phenoxy)-6-(trifluoromethyl)pyridin-3-amine was prepared from tert-butyl N-[5-chloro-2-(3,4-difluoro-2-methyl-phenoxy)-6-(trifluoromethyl)-3- pyridyl]carbamate using a procedure analogous to that found in Intermediate B - 11, step 6.
  • Step 1 methyl 2-(4,4-difluoroazepan-1-yl)-5-methyl-6-(trifluoromethyl)pyridine-3- carboxylate
  • Methyl 2-(4,4-difluoroazepan-1-yl)-5-methyl-6-(trifluoromethyl)pyridine-3-carboxylate was prepared from methyl 2-chloro-5-methyl-6-(trifluoromethyl)pyridine-3-carboxylate (Intermediate B - 11, step 2) and 4,4-difluoroazepane using a procedure analogous to that found in Intermediate B - 20, step 1 using cesium carbonate as the base and DMF as solvent.
  • Step 2 1-(5-chloro-3-iodo-4,6-dimethyl-2-pyridyl)-4,4-difluoro-azepane
  • Step 3 [2-(4,4-difluoroazepan-1-yl)-5,6,7,8-tetrahydroquinolin-3-yl]boronic acid
  • [2-(4,4-difluoroazepan-1-yl)-5,6,7,8-tetrahydroquinolin-3-yl]boronic acid was prepared from 3-Bromo-2-(4,4-difluoroazepan-1-yl)-5,6,7,8-tetrahydroquinoline using a procedure analogous to that found in Intermediate B - 20, step 2.
  • ESI-MS m/z calc.310.17, found 311.2 (M+1) + .
  • Step 2 2-bromo-6-tert-butyl-5-chloro-pyridine-3-carbonitrile
  • Step 3 5-bromo-2-(3,3-difluorocyclobutyl)-4-(4,4-difluorocyclohexyl)pyrimidine
  • 5-Bromo-2-(3,3-difluorocyclobutyl)-4-(4,4-difluorocyclohexyl)pyrimidine was prepared from 5-Bromo-2-(3,3-difluorocyclobutyl)-6-(4,4-difluorocyclohexyl)pyrimidine-4-carboxylic acid using a procedure analogous to that found in Intermediate B - 40, step 3 with heating at 60 oC for 90 min.
  • Step 3 [6-[[3-bromo-4-methyl-5-(trifluoromethyl)-2-pyridyl]oxy]-2,3-difluoro- phenyl]methoxy-tert-butyl-dimethyl-silane [00949] [6-[[3-Bromo-4-methyl-5-(trifluoromethyl)-2-pyridyl]oxy]-2,3-difluoro-phenyl]methoxy- tert-butyl-dimethyl-silane was prepared from 2-[[tert-butyl(dimethyl)silyl]oxymethyl]-3,4-difluoro- phenol using a procedure analogous to that found in Intermediate B - 64, step 2.
  • Step 2 [6-(3,3-difluorocyclobutyl)-4-(3,4-difluoro-2-methyl-phenoxy)-3-pyridyl]boronic acid
  • Step 2 A mixture of the protected intermediate I and Pd/C is stirred in the appropriate solvent (e.g. methanol, ethanol, or ethyl acetate) under an atmosphere of hydrogen. The reaction mixture is filtered, concentrated, and purified via silica gel column chromatography or reverse phase column chromatography to provide the desired product I.
  • the appropriate solvent e.g. methanol, ethanol, or ethyl acetate
  • the reaction mixture is filtered, concentrated, and purified via silica gel column chromatography or reverse phase column chromatography to provide the desired product I.
  • a solution of protected intermediate I in the appropriate solvent DCM, dioxane or toluene
  • acid e.g. HCl or TFA
  • Step 2 4-benzyloxy-5-chloro-2-[2-(3,4-difluoro-2-methyl-phenoxy)-3-quinolyl]-1,6- naphthyridine
  • Step 3 4-Benzyloxy-2-[2-(3,4-difluoro-2-methyl-phenoxy)-3-quinolyl]-6-oxido-1,6- naphthyridin-6-ium (100 mg, 0.192 mmol) was treated with POCl 3 (400 ⁇ L, 4.29 mmol) and stirred at 50 °C for 2 h and then concentrated in vacuo.
  • Step 2 tert-butyl 2-(3,4-difluoro-2-methoxy-phenoxy)-5-fluoro-4- (trifluoromethyl)benzoate
  • tert-Butyl 2,5-difluoro-4-(trifluoromethyl)benzoate (69.8 g, 247 mmol)
  • 3,4-difluoro-2- methoxy-phenol 55 g, 344 mmol
  • cesium carbonate 140 g, 430 mmol
  • reaction mixture was quenched in an aqueous sodium bisulfite solution (10% w/w, 100 mL). The mixture was then filtered and the solid recovered in MTBE (50 mL), filtered on silica (10 g) and washed with MTBE (50 mL). Evaporation afforded 2-[2-(3,4-difluoro-2-methoxy-phenoxy)-5-fluoro-4- (trifluoromethyl)phenyl]-4-oxo-1H-1,6-naphthyridine-5-carboxamide (142, 2.05 g, 60%) as a beige solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/US2023/019469 2022-04-22 2023-04-21 Heteroaryl compounds for the treatment of pain Ceased WO2023205463A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
PE2024002287A PE20251179A1 (es) 2022-04-22 2023-04-21 Compuestos de heteroarilo para el tratamiento del dolor
JP2024562079A JP2025513455A (ja) 2022-04-22 2023-04-21 疼痛の治療のためのヘテロアリール化合物
AU2023256603A AU2023256603A1 (en) 2022-04-22 2023-04-21 Heteroaryl compounds for the treatment of pain
CR20240513A CR20240513A (es) 2022-04-22 2023-04-21 Compuestos de heteroarilo para el tratamiento del dolor
IL316462A IL316462A (en) 2022-04-22 2023-04-21 Heteroaryl compounds for the treatment of pain
CN202380047901.3A CN119677737A (zh) 2022-04-22 2023-04-21 用于治疗疼痛的杂芳基化合物
EP23724521.2A EP4511116A1 (en) 2022-04-22 2023-04-21 Heteroaryl compounds for the treatment of pain
KR1020247039041A KR20250005373A (ko) 2022-04-22 2023-04-21 통증 치료를 위한 헤테로아릴 화합물
DO2024000209A DOP2024000209A (es) 2022-04-22 2024-10-21 Compuestos de heteroarilo para el tratamiento del dolor
JOJO/P/2024/0235A JOP20240235A1 (ar) 2022-04-22 2024-10-22 مركبات أريل غير متجانسة لمعالجة الألم
MX2024013020A MX2024013020A (es) 2022-04-22 2024-10-22 Compuestos de heteroarilo para el tratamiento del dolor
CONC2024/0015820A CO2024015820A2 (es) 2022-04-22 2024-11-21 Compuestos de heteroarilo para el tratamiento del dolor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263333875P 2022-04-22 2022-04-22
US63/333,875 2022-04-22

Publications (2)

Publication Number Publication Date
WO2023205463A1 true WO2023205463A1 (en) 2023-10-26
WO2023205463A8 WO2023205463A8 (en) 2024-03-28

Family

ID=86387166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/019469 Ceased WO2023205463A1 (en) 2022-04-22 2023-04-21 Heteroaryl compounds for the treatment of pain

Country Status (19)

Country Link
US (1) US12503439B2 (https=)
EP (1) EP4511116A1 (https=)
JP (1) JP2025513455A (https=)
KR (1) KR20250005373A (https=)
CN (1) CN119677737A (https=)
AR (1) AR129104A1 (https=)
AU (1) AU2023256603A1 (https=)
CL (1) CL2024003232A1 (https=)
CO (1) CO2024015820A2 (https=)
CR (1) CR20240513A (https=)
DO (1) DOP2024000209A (https=)
GE (1) GEAP202516632A (https=)
IL (1) IL316462A (https=)
JO (1) JOP20240235A1 (https=)
MX (1) MX2024013020A (https=)
PE (1) PE20251179A1 (https=)
TW (1) TW202404969A (https=)
UY (1) UY40234A (https=)
WO (1) WO2023205463A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025090511A1 (en) * 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025098515A1 (en) * 2023-11-10 2025-05-15 Danatlas Pharmaceuticals Co., Ltd. Heterocyclic derivatives, compositions and uses thereof
WO2025240895A1 (en) * 2024-05-17 2025-11-20 Siteone Therapeutics, Inc. SUBSTITUTED CYCLOALKYL AND HETEROCYCLOALKYL INHIBITORS OF NAv1.8 FOR THE TREATMENT OF PAIN
WO2025256572A1 (zh) * 2024-06-13 2025-12-18 海思科医药集团股份有限公司 一种Nav1.8抑制剂及其在医药上的应用
WO2026001999A1 (zh) * 2024-06-25 2026-01-02 江苏恒瑞医药股份有限公司 芳香环类化合物、其制备方法及其在医药上的应用
WO2026008013A1 (zh) * 2024-07-03 2026-01-08 江苏恒瑞医药股份有限公司 氧代杂芳基类化合物、其制备方法及其在医药上的应用
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain
WO2026057012A1 (zh) * 2024-09-12 2026-03-19 江苏恒瑞医药股份有限公司 芳香环类化合物、其制备方法及其在医药上的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Citations (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO2006011050A2 (en) 2004-07-23 2006-02-02 Pfizer Limited Pyridine derivatives
WO2008135826A2 (en) 2007-05-03 2008-11-13 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
WO2010129864A2 (en) 2009-05-07 2010-11-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US20120196869A1 (en) 2011-02-02 2012-08-02 Sara Sabina Hadida Ruah Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
WO2012112743A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
WO2012116440A1 (en) 2011-03-03 2012-09-07 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
WO2012125973A2 (en) 2011-03-16 2012-09-20 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
WO2012125613A1 (en) 2011-03-14 2012-09-20 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
WO2013061205A2 (en) 2011-10-26 2013-05-02 Pfizer Limited Chemical compounds
WO2013086229A1 (en) 2011-12-07 2013-06-13 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
US8466188B2 (en) 2006-10-12 2013-06-18 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2013109521A1 (en) 2012-01-16 2013-07-25 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
US20130303535A1 (en) 2008-12-26 2013-11-14 Dainippon Sumitomo Pharma Co., Ltd. Novel bicyclic heterocyclic compound
US20140213616A1 (en) 2013-01-31 2014-07-31 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels
WO2014120820A1 (en) 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
WO2014120815A1 (en) 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Quinoline and quinazoline amides as modulators of sodium channels
US8883840B2 (en) 2009-06-29 2014-11-11 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
WO2014201206A1 (en) 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
WO2015010065A1 (en) 2013-07-19 2015-01-22 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
US20150166589A1 (en) 2013-12-13 2015-06-18 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
WO2016141035A1 (en) 2015-03-02 2016-09-09 Amgen Inc. Bicyclic ketone sulfonamide compounds
WO2017059385A1 (en) 2015-09-30 2017-04-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2018183781A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2018183782A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2018213426A1 (en) 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
US20190016671A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020014243A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
WO2020014246A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
WO2020072835A1 (en) 2018-10-03 2020-04-09 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2020092667A1 (en) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
WO2020092187A1 (en) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
CN111217776A (zh) 2020-01-19 2020-06-02 中国人民解放军军事科学院军事医学研究院 含苯并杂环结构的酰胺衍生物、组合物和应用
WO2020117626A1 (en) 2018-12-05 2020-06-11 Merck Sharp & Dohme Corp. 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
WO2020140959A1 (zh) 2019-01-04 2020-07-09 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020144375A1 (en) 2019-01-11 2020-07-16 Grünenthal GmbH Substituted pyrrolidine amides iii
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020151728A1 (zh) 2019-01-25 2020-07-30 江苏恒瑞医药股份有限公司 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN111808019A (zh) 2020-09-08 2020-10-23 上海济煜医药科技有限公司 一种并环化合物及其应用
WO2020261114A1 (en) 2019-06-27 2020-12-30 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
CN112225695A (zh) 2020-12-15 2021-01-15 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途
CN112300051A (zh) 2019-07-31 2021-02-02 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN112300069A (zh) 2019-07-31 2021-02-02 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN112390745A (zh) 2019-08-19 2021-02-23 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
WO2021032074A1 (zh) 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CN112441969A (zh) 2019-08-30 2021-03-05 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN112457294A (zh) 2021-01-27 2021-03-09 上海济煜医药科技有限公司 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途
CN112479996A (zh) 2019-09-12 2021-03-12 上海济煜医药科技有限公司 吡啶氮氧化合物及其制备方法和用途
WO2021252820A1 (en) 2020-06-10 2021-12-16 Amgen Inc. Cyclobutyl dihydroquinoline sulfonamide compounds
WO2021252822A1 (en) 2020-06-10 2021-12-16 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
WO2021252818A1 (en) 2020-06-10 2021-12-16 Amgen Inc. Cyclopropyl dihydroquinoline sulfonamide compounds
WO2021257490A1 (en) 2020-06-17 2021-12-23 Merck Sharp & Dohme Corp. 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
WO2021257420A1 (en) 2020-06-17 2021-12-23 Merck Sharp & Dohme Corp. 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors
WO2021257418A1 (en) 2020-06-17 2021-12-23 Merck Sharp & Dohme Corp. 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors
WO2022036297A1 (en) 2020-08-14 2022-02-17 Siteone Therapeutics, Inc. Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
CN114591293A (zh) 2020-12-07 2022-06-07 成都康弘药业集团股份有限公司 作为Nav1.8抑制剂的并环化合物及其用途
WO2022235558A1 (en) 2021-05-07 2022-11-10 Merck Sharp & Dohme Llc Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
WO2022235859A1 (en) 2021-05-07 2022-11-10 Merck Sharp & Dohme Llc Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
WO2022263498A1 (en) 2021-06-15 2022-12-22 Grünenthal GmbH Substituted pyrazole amides

Family Cites Families (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
CA1317298C (en) 1987-03-03 1993-05-04 Upjohn Company (The) Antibiotic sulfonylaminocarbonyl activated .beta.-lactams
ATE130299T1 (de) 1987-07-23 1995-12-15 Zeneca Pharma Sa Cephalosporinverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische präparate.
US4950585A (en) 1987-08-18 1990-08-21 Konica Corporation Coupler for photographic use
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
JP2952706B2 (ja) 1990-10-26 1999-09-27 大塚化学株式会社 ４―キノロン誘導体の製造法
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
IT1254469B (it) 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
HRP930210A2 (en) 1992-02-25 1995-06-30 Recordati Chem Pharm Heterobicyclic compounds and pharmaceutical preparations containing them
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
DE4233717A1 (de) 1992-10-07 1994-04-14 Bayer Ag Substituierte 3,4-Hetaryl-pyrazoline
TW299333B (https=) 1992-12-29 1997-03-01 Takeda Pharm Industry Co Ltd
PL322452A1 (en) 1995-03-10 1998-02-02 Sanofi Pharmaceuticals 6-arylpyrasole [3,4-d]pyrimidin-4-ones, preparations containing such compounds and methods of mking use of them
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6060477A (en) 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
AU4153496A (en) 1995-10-20 1997-05-07 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US6080757A (en) 1996-06-06 2000-06-27 Pfizer Inc Antibiotic quinolones and derivatives
US5700821A (en) 1996-07-30 1997-12-23 University Of Pittsburgh Phosphatase inhibitors and methods of use thereof
CA2268399C (en) 1996-10-31 2008-08-19 Harbor Branch Oceanographic Institution, Inc. Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
WO1998027080A1 (en) 1996-12-19 1998-06-25 Agrevo Uk Limited Chromones useful as fungicides
US5942508A (en) 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
US6274592B1 (en) 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
US5994367A (en) 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
RS50011B (sr) 1998-04-20 2008-09-29 Pfizer Inc., Derivati piridin-3-karboksilne kiseline i njihova upotreba kao intermedijera
JP4611524B2 (ja) 1998-06-02 2011-01-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピロロ［２，３ｄ］ピリミジン組成物およびその使用
BR9915532A (pt) 1998-10-23 2001-08-14 Pfizer Inibidores de cgmp pde5 de pirazolopirimidinona para tratamento da disfunção sexual
JP3539628B2 (ja) 1999-09-17 2004-07-07 富士写真フイルム株式会社 発光素子材料、それを使用した発光素子およびアミン化合物
HK1049834A1 (zh) 1999-10-11 2003-05-30 辉瑞大药厂 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
MXPA02006461A (es) 1999-12-31 2003-09-05 Texas Biotechnology Corp Sulfonamidas y derivados de las mismas que modulan la actividad de endotelina.
AU5553801A (en) 2000-04-24 2001-11-07 Bristol Myers Squibb Co Heterocycles that are inhibitors of impdh enzyme
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
AU2001275881B2 (en) 2000-07-10 2006-04-06 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods
YU51701A (sh) 2000-07-28 2003-12-31 Pfizer Inc. Postupak za dobijanje jedinjenja pirazola/4,3-d/ pirimidin-7-ona i njihovih derivata
GB0023918D0 (en) 2000-09-29 2000-11-15 King S College London Antiparasitic compounds
GB0025782D0 (en) 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
JP2002189128A (ja) 2000-12-22 2002-07-05 Fuji Photo Film Co Ltd 光学フイルム、偏光選択素子、偏光板および液晶表示装置
KR20080079341A (ko) 2001-01-16 2008-08-29 아스트라제네카 아베 치료용 헤테로시클릭 화합물
MXPA03006478A (es) 2001-01-26 2003-09-22 Pharmacia Italia Spa Derivados de cromano, procedimiento para su preparacion y su uso como agentes antitumorales.
GB0106661D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
ES2572030T3 (es) 2001-08-10 2017-07-19 Shionogi & Co., Ltd. Agente antiviral
SE0103648D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
GB0130416D0 (en) 2001-12-20 2002-02-06 Eastman Kodak Co Photographic elements containing a de-aggregating compound dye-forming coupler and stabilizer
GB0130418D0 (en) 2001-12-20 2002-02-06 Eastman Kodak Co Photographic elements containing a deaggregating compound and dye forming coupler
US20050244718A1 (en) 2002-07-01 2005-11-03 Eike Poetsch Polymerizable, luminescent compounds and mixtures, luminescent polymer materials and their use
US7598377B2 (en) 2002-08-16 2009-10-06 Astrazeneca Ab Inhibition of phosphoinositide 3-kinase β
CA2506897A1 (en) 2002-12-27 2004-07-15 Tibotec Bvba Fluorogenic enzyme substrates and methods of preparation
JP2005008789A (ja) 2003-06-20 2005-01-13 Toray Ind Inc 有機エレクトロルミネッセンス用材料、および有機エレクトロルミネッセンス用材料の製造方法、ならびに有機エレクトロルミネッセンス素子
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
MXPA06001002A (es) 2003-07-25 2006-04-11 Amgen Inc Piridonas y pirimidinonas sustituidas con propiedades antiinflamatorias.
JP4795634B2 (ja) 2003-10-31 2011-10-19 出光興産株式会社 有機薄膜トランジスタ
WO2005047279A1 (en) 2003-11-10 2005-05-26 Merck Sharp & Dohme Limited Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain
JP4521182B2 (ja) 2003-12-26 2010-08-11 富士フイルム株式会社 有機電界発光素子
WO2005071096A2 (en) 2004-01-21 2005-08-04 Molecular Probes, Inc. Derivatives of cephalosporin and clavulanic acid for detecting beta-lacamase in a sample
US7119214B2 (en) 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
WO2005103052A1 (en) 2004-04-21 2005-11-03 Pfizer Products Inc. Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof
JP4953297B2 (ja) 2004-09-15 2012-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
GB0421911D0 (en) 2004-10-01 2004-11-03 Univ Cambridge Tech Methods and means
WO2006038041A1 (en) 2004-10-08 2006-04-13 Merck Sharp & Dohme Limited Besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain
US8697674B2 (en) 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
ES2359931T3 (es) 2005-03-11 2011-05-30 Merck Patent Gmbh Tetrahidro- y dihidroquinazolinonas.
WO2006100119A1 (en) 2005-03-24 2006-09-28 Glaxo Group Limited Derivatives of imidazo (1,2-a) pyridine useful as medicaments for treating gastrointestinal diseases
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
JP2008546843A (ja) 2005-06-27 2008-12-25 アムゲン インコーポレイティッド 抗炎症性アリールニトリル化合物
ATE519757T1 (de) 2005-10-11 2011-08-15 Centre Nat Rech Scient 3 hydroxyflavon-derivate zur erkennung und quantifizierung von zell-apoptosen
EP1966184B1 (en) 2005-12-20 2010-08-25 NeuroSearch A/S Pyridinyl-quinazoline derivatives and their medical use
MX2008008529A (es) 2005-12-29 2008-09-26 Organon Nv Inhibidores de amida hidrolasa de acido graso.
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
US20090264342A1 (en) 2006-02-13 2009-10-22 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
JP2007230145A (ja) 2006-03-02 2007-09-13 Mitsubishi Chemicals Corp 光学記録媒体の記録層形成用色素、及びそれを用いた光学記録媒体、その光学記録媒体の記録方法
SI2656842T1 (sl) 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
EP2004596A2 (en) 2006-04-11 2008-12-24 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
WO2008024139A2 (en) 2006-08-18 2008-02-28 N.V. Organon Inhibitors of fatty acid amide hydrolase
US20100173332A1 (en) 2006-09-07 2010-07-08 Auckland Uniservices Limited Method for the Fluorescent Detection of Nitroreductase Activity Using Nitro-Substituted Aromatic Compounds
US20080234355A1 (en) 2006-09-11 2008-09-25 Xiong Cai Dna methyl transferase inhibitors containing a zinc binding moiety
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
JP2010502741A (ja) 2006-09-11 2010-01-28 キュリス，インコーポレイテッド Ｐｔｋインヒビターとしての亜鉛結合部分を含む置換２−インドリノン
AU2007296746B2 (en) 2006-09-11 2012-07-05 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
WO2008037607A1 (de) 2006-09-25 2008-04-03 Basf Se Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
RU2469034C2 (ru) 2006-12-04 2012-12-10 Астразенека Аб Химические соединения
DE102006059710A1 (de) 2006-12-18 2008-06-19 Freie Universität Berlin Substituierte 4-Hydroxypyridine
EP2122350A4 (en) 2007-01-04 2010-10-27 Do Coop Technologies Ltd PROOF OF ANALYTES
US20080176225A1 (en) 2007-01-18 2008-07-24 Steve Roffler Membrane bound reporter gene system
WO2008094507A2 (en) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
CN101674833A (zh) 2007-03-20 2010-03-17 柯瑞斯公司 含有锌结合半族的Raf激酶抑制剂
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
ES2637999T3 (es) 2007-05-17 2017-10-18 Helperby Therapeutics Limited Uso de compuestos de 4-(pirrolidin-1-il)quinolina para eliminar microorganismos clínicamente latentes
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
AU2008310660A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
KR20100075631A (ko) 2007-10-11 2010-07-02 버텍스 파마슈티칼스 인코포레이티드 전압­개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드
WO2009049181A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
EP2247558B2 (en) 2008-02-14 2024-07-03 Eli Lilly and Company Novel imaging agents for detecting neurological dysfunction
JP5530599B2 (ja) 2008-02-28 2014-06-25 富士フイルム株式会社 フォトレジスト液、およびこれを用いるエッチング方法
WO2009114470A2 (en) 2008-03-10 2009-09-17 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
EP2262366A4 (en) 2008-04-18 2012-02-22 Shenogen Pharma Group Ltd COMPOUNDS AND METHODS FOR TREATING STROGEN RECEPTOR-RELATED DISEASES
AU2009254928A1 (en) 2008-06-04 2009-12-10 Astrazeneca Ab Thiazolo [5, 4-B] pyridine and oxazolo [5, 4-B] pyridine derivatives as antibacterial agents
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
MX2010014066A (es) 2008-06-16 2011-06-01 Univ Tennessee Res Foundation Compuestos para el tratamiento del cancer.
GB0815962D0 (en) 2008-09-02 2008-10-08 Merlion Pharmaceuticals Pte Ltd Hybrid antibacterial compounds and their use
MX2011003373A (es) 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Quinazolinona, quinolona y analogos relacionados como moduladores de sirtuina.
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US8491891B2 (en) 2008-11-26 2013-07-23 Academia Sinica Human beta-glucuronidase mutants with elevated enzymatic activity under physiological conditions and method for identifying such
JP2012512863A (ja) 2008-12-19 2012-06-07 ファイザー・インク モノカルバム
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
EP2264035A1 (en) 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
CN101906105B (zh) 2009-06-08 2013-01-16 河北医科大学 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途
US20110124597A1 (en) 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
WO2011047320A2 (en) 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
JP2013525308A (ja) 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
WO2011160024A2 (en) 2010-06-17 2011-12-22 Fuzians Biomedicals, Inc. Compounds useful as antiviral agents, compositions, and methods of use
US8889638B2 (en) 2010-06-22 2014-11-18 The Regents Of The University Of California Stimulus-triggered prodrugs
US8524740B2 (en) 2010-07-15 2013-09-03 Tairx, Inc. Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives
AU2011282776B2 (en) 2010-07-27 2014-06-12 Boston Medical Center Corporation Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
GB201017315D0 (en) 2010-10-13 2010-11-24 Antoxis Ltd Compound
GB201020076D0 (en) 2010-11-26 2011-01-12 Liverpool School Tropical Medicine Antimalarial compounds
DK2646436T3 (en) 2010-11-29 2015-06-29 Pfizer monobactams
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
TWI574687B (zh) 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
US10953012B2 (en) 2011-04-26 2021-03-23 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
AU2012250059A1 (en) 2011-04-26 2013-10-10 Elexopharm Gmbh Aldosterone synthase inhibitors
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
WO2012170371A1 (en) 2011-06-10 2012-12-13 N30 Pharmaceuticals, Llc Compounds as s-nitrosoglutathione reductase inhibitors
CN103717591B (zh) 2011-07-27 2016-08-24 Ab科学有限公司 作为选择性蛋白激酶(c-kit)抑制剂的噁唑和噻唑衍生物
WO2013022740A2 (en) 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof
US9605296B2 (en) 2011-09-29 2017-03-28 Ecole Normale Superieure De Lyon Fluorogenic peptidase substrate
CA2850551A1 (en) 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
CN103159738B (zh) 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用
US9732085B2 (en) 2011-12-21 2017-08-15 Ono Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor Xia
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20140005181A1 (en) 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
TWI520962B (zh) 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
WO2014018741A1 (en) 2012-07-27 2014-01-30 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
FR2994180B1 (fr) 2012-08-02 2014-08-22 Ecole Norm Superieure Lyon Substrat de glycosidase fluorogene et procede de detection associe
US9403845B2 (en) 2012-08-20 2016-08-02 Syngenta Participations Ag Pesticidally active pyridyl- and pyrimidyl- substituted pyrazole derivatives
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
US10392389B2 (en) 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
WO2014070978A1 (en) 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
CA2890897A1 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt)
CN103848818B (zh) 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
CN103848821B (zh) 2012-11-29 2016-10-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
HK1211287A1 (en) 2013-01-08 2016-05-20 Savira Pharmaceuticals Gmbh Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease
ES2716379T3 (es) 2013-02-20 2019-06-12 Basf Se Compuestos de antranilamida, sus mezclas y el uso de los mismos como pesticidas
KR20150130491A (ko) 2013-03-13 2015-11-23 제넨테크, 인크. 피라졸로 화합물 및 그것의 용도
WO2014179496A1 (en) 2013-04-30 2014-11-06 Afraxis Holdings, Inc. Serine/threonine kinase inhibitors
US20140323477A1 (en) 2013-04-30 2014-10-30 Genentech, Inc. Serine/threonine kinase inhibitors
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
AU2014310371A1 (en) 2013-08-21 2016-03-10 Resverlogix Corp. Compositions and therapeutic methods for accelerated plaque regression
WO2015035051A1 (en) 2013-09-04 2015-03-12 Board Of Regents Of The University Of Texas System Methods and compositions for selective and targeted cancer therapy
EP3041474B1 (en) 2013-09-05 2020-03-18 Genentech, Inc. Antiproliferative compounds
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
CN104761524A (zh) 2014-01-07 2015-07-08 清华大学 一种化合物及其在制备抗寄生虫病药物中的应用
CN105829298B (zh) 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
FR3022784B1 (fr) 2014-06-26 2017-09-08 Ecole Normale Superieure Lyon Sondes moleculaires activables hydrosolubles, intermediaires pour leur synthese et procedes de detection associes
US9818959B2 (en) 2014-07-29 2017-11-14 Arizona Board of Regents on behlaf of Arizona State University Metal-assisted delayed fluorescent emitters containing tridentate ligands
JP2016079098A (ja) 2014-10-10 2016-05-16 塩野義製薬株式会社 セフェム化合物
BR112017012146B1 (pt) 2014-12-10 2023-11-21 Ono Pharmaceutical Co., Ltd Composto derivado de di-hidroindolizinona, seu uso, composição farmacêutica e inibidor de fxia
CN105936635B (zh) 2015-03-06 2019-06-21 南京圣和药业股份有限公司 作为磷脂酰肌醇3-激酶δ抑制剂的化合物及其应用
CN106008479B (zh) 2015-03-06 2020-01-10 南京圣和药业股份有限公司 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用
GB201507464D0 (en) 2015-04-30 2015-06-17 Syngenta Participations Ag Herbicidal compounds
GB201507463D0 (en) 2015-04-30 2015-06-17 Syngenta Participations Ag Herbicidal compounds
CN108349968A (zh) 2015-07-28 2018-07-31 维奥梅生物科学私人有限公司 抗菌治疗剂和预防剂
DE102015121035A1 (de) 2015-12-03 2017-06-08 Airbus Defence and Space GmbH Verfahren zur Detektion coliformer Keime
GB201522232D0 (en) 2015-12-16 2016-01-27 Liverpool School Tropical Medicine Combination product
CN106946775B (zh) 2016-01-07 2020-04-10 清华大学 一种化合物及其在制备抗丙肝病毒药物中的应用
WO2017156194A1 (en) 2016-03-08 2017-09-14 The Regents Of The University Of California Compositions and methods for inhibiting influenza rna polymerase pa endonuclease
US10889556B2 (en) 2016-03-08 2021-01-12 The Regents Of The University Of California Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease
JP6992284B2 (ja) 2016-06-06 2022-01-13 小野薬品工業株式会社 ジヒドロインドリジノン誘導体を含有する医薬組成物
EP3260445A1 (en) 2016-06-24 2017-12-27 Universität Konstanz Compounds for use as an anti-bacterial or anti-fungal agent and as a zinc sensor
GB201612938D0 (en) 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
CN107661333B (zh) 2016-07-27 2020-12-29 清华大学 化合物在治疗肺癌中的应用
RS63872B1 (sr) 2016-08-19 2023-02-28 Univ Bristol Derivati citizina za lečenje zavisnosti
CN107773562B (zh) 2016-08-25 2020-04-07 清华大学 化合物在抗登革和寨卡病毒感染中的应用
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
EP3309154A1 (en) 2016-10-13 2018-04-18 Universite De Geneve New compounds and uses thereof for detection of target molecules in a sample
FR3060567B1 (fr) 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
CN109369640B (zh) 2017-01-13 2020-03-27 苏州爱科百发生物医药技术有限公司 一种二氢异喹啉类化合物的制备方法
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CN108623588A (zh) 2017-03-24 2018-10-09 中国海洋大学 一种含内酰胺的四环衍生物及其制备方法和应用
CN108623562A (zh) 2017-03-24 2018-10-09 中国海洋大学 一种喹啉酮生物碱类化合物及其制备方法和应用
CN108623587A (zh) 2017-03-24 2018-10-09 中国海洋大学 一种含羰基的胺类化合物及其制备方法和用途
JP2020100564A (ja) 2017-04-03 2020-07-02 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
WO2018204765A1 (en) 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
CN106977486B (zh) 2017-05-25 2019-09-24 南方科技大学 一种手性二氢黄酮类化合物及其衍生物的制备方法和应用
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
CN107365326B (zh) 2017-07-24 2019-08-20 湖北大学 一种用于检测活细胞内氟离子的荧光探针及其制备方法
JP2020529432A (ja) 2017-08-04 2020-10-08 アキシャル バイオセラピューティクス, インク.Axial Biotherapeutics, Inc. 微生物により誘発されるアミロイドの阻害剤
EP3502095A1 (en) 2017-12-22 2019-06-26 Universität Konstanz Compound for use against pathogenic neisseria and haemophilus species and moraxella catarrhalis
CN111315744B (zh) 2018-01-09 2023-07-14 四川科伦博泰生物医药股份有限公司 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
CN108329366A (zh) 2018-03-07 2018-07-27 南京工业大学 一种用于检测β-半乳糖苷酶的荧光探针化合物及其制备方法
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
TWI815887B (zh) 2018-05-15 2023-09-21 美商愛彼特生物製藥股份有限公司 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
EP3802544A1 (en) 2018-06-05 2021-04-14 RAPT Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
WO2019238057A1 (zh) 2018-06-13 2019-12-19 中国科学院上海有机化学研究所 Fso 2n 3在制备叠氮化合物中的应用
TWI812739B (zh) 2018-06-21 2023-08-21 景凱生物科技股份有限公司 Nadph氧化酶抑制劑、含其的醫藥組合物、及其應用
WO2020003219A1 (en) 2018-06-29 2020-01-02 Oat & Iil India Laboratories Private Limited Substituted pyrazole derivatives as insecticides and fungicides
CA3114987A1 (en) 2018-08-27 2020-03-05 Beijing Yuezhikangtai Biomedicines Co., Ltd. Multi-substituted pyridone derivatives and medical use thereof
JP2021536458A (ja) 2018-09-04 2021-12-27 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. アリール炭化水素レセプター・アンタゴニスト及び使用方法
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
CN111153899B (zh) 2018-11-08 2023-12-01 四川科伦博泰生物医药股份有限公司 一种取代吡啶化合物、其制备方法和用途
CN111727186B (zh) 2018-11-11 2022-11-08 上海海雁医药科技有限公司 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途
CN113226309B (zh) 2018-12-03 2024-10-29 珠海岐微生物科技有限公司 一种治疗年龄相关性黄斑变性的方法
WO2020118036A1 (en) 2018-12-06 2020-06-11 The Children's Medical Center Corporation Antibacterial compounds and uses thereof
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
CN111848731B (zh) 2019-04-19 2022-11-29 国家纳米科学中心 一种原位自组装的抗菌分子及其制备方法和应用
CN110498784B (zh) 2019-05-20 2022-06-14 广东克冠达医药科技有限公司 一类川陈皮素衍生物或其药学上可接受的盐及其制备方法和应用
WO2021011727A1 (en) 2019-07-18 2021-01-21 Bristol-Myers Squibb Company PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CN112812014B (zh) 2019-11-15 2024-05-10 石家庄诚志永华显示材料有限公司 化合物、液晶组合物、液晶显示器
US20230057033A1 (en) 2019-11-29 2023-02-23 Molsid Fluorogenic beta-lactamase substrate and associated detection method
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
JP2023507816A (ja) 2019-12-20 2023-02-27 エンジン バイオサイエンシズ プライベート リミテッド がんを治療するための方法及び組成物
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
WO2021155253A1 (en) 2020-01-31 2021-08-05 Atomwise Inc. Anat inhibitors and methods of use thereof
CN112047880B (zh) 2020-10-15 2022-11-01 天津科技大学 一类氮杂黄酮衍生物及其作为抗肿瘤药物的应用
CN112778288B (zh) 2021-01-22 2022-08-09 湖南大学 一种近红外固态发光的荧光探针及其制备方法与应用
CN113200926B (zh) 2021-05-10 2022-09-23 四川大学 一种修饰2-芳基喹唑啉-4(3h)-酮类化合物的方法
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
HRP20260068T1 (hr) 2021-06-04 2026-02-27 Vertex Pharmaceuticals Incorporated Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
AU2022283934A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CN113754594B (zh) 2021-09-16 2025-01-21 中国药科大学 喹唑啉酮类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途
US20230382910A1 (en) * 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Patent Citations (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO2006011050A2 (en) 2004-07-23 2006-02-02 Pfizer Limited Pyridine derivatives
US20080312235A1 (en) 2004-07-23 2008-12-18 Charlotte Alice Louise Lane Pyridine Derivatives
US8466188B2 (en) 2006-10-12 2013-06-18 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US20090048306A1 (en) 2007-05-03 2009-02-19 Pfizer, Inc. Pyridine derivatives
WO2008135826A2 (en) 2007-05-03 2008-11-13 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
US20130303535A1 (en) 2008-12-26 2013-11-14 Dainippon Sumitomo Pharma Co., Ltd. Novel bicyclic heterocyclic compound
WO2010129864A2 (en) 2009-05-07 2010-11-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
US8883840B2 (en) 2009-06-29 2014-11-11 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US20120220605A1 (en) 2009-09-04 2012-08-30 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US20110306607A1 (en) 2010-05-06 2011-12-15 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US20120196869A1 (en) 2011-02-02 2012-08-02 Sara Sabina Hadida Ruah Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
WO2012106499A1 (en) 2011-02-02 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
WO2012112743A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
US20120245136A1 (en) 2011-02-18 2012-09-27 Sara Sabina Hadida-Ruah Chroman-spirocyclic piperidine amides as modulators of ion channels
WO2012116440A1 (en) 2011-03-03 2012-09-07 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
US20140187533A1 (en) 2011-03-03 2014-07-03 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
WO2012125613A1 (en) 2011-03-14 2012-09-20 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
US20120264749A1 (en) 2011-03-14 2012-10-18 Sara Sabina Hadida-Ruah Morpholine-spirocyclic piperidine amides as modulators of ion channels
WO2012125973A2 (en) 2011-03-16 2012-09-20 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
WO2013061205A2 (en) 2011-10-26 2013-05-02 Pfizer Limited Chemical compounds
US20140296313A1 (en) 2011-10-26 2014-10-02 Pfizer Limited (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators
WO2013086229A1 (en) 2011-12-07 2013-06-13 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
WO2013109521A1 (en) 2012-01-16 2013-07-25 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
US20150005304A1 (en) 2012-01-16 2015-01-01 Vertex Pharmaceuticals Incorporated Pyran-Spirocyclic Piperidine Amides as Modulators of Ion Channels
US20130274243A1 (en) 2012-02-03 2013-10-17 Pfizer Limited Chemical Compounds
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
WO2014120808A1 (en) 2013-01-31 2014-08-07 Vertex Parmaceuticals Incorporated Pyridone amides as modulators of sodium channels
US20140221435A1 (en) 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
WO2014120815A1 (en) 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Quinoline and quinazoline amides as modulators of sodium channels
US20140228371A1 (en) 2013-01-31 2014-08-14 Vertex Pharmaceuticals Incorporated Quinoline and quinazoline amides as modulators of sodium channels
WO2014120820A1 (en) 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
US20140213616A1 (en) 2013-01-31 2014-07-31 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels
WO2014120808A9 (en) 2013-01-31 2015-05-14 Vertex Parmaceuticals Incorporated Pyridone amides as modulators of sodium channels
WO2014201206A1 (en) 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
WO2014201173A1 (en) 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
WO2015010065A1 (en) 2013-07-19 2015-01-22 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
US20160152561A1 (en) 2013-07-19 2016-06-02 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
WO2015089361A1 (en) 2013-12-13 2015-06-18 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US20150166589A1 (en) 2013-12-13 2015-06-18 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
WO2016141035A1 (en) 2015-03-02 2016-09-09 Amgen Inc. Bicyclic ketone sulfonamide compounds
WO2017059385A1 (en) 2015-09-30 2017-04-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2018183781A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2018183782A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2018213426A1 (en) 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
US20190016671A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2019014352A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS
WO2020014243A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
WO2020014246A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
WO2020072835A1 (en) 2018-10-03 2020-04-09 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
US20200140411A1 (en) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
WO2020092667A1 (en) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
WO2020092187A1 (en) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
WO2020117626A1 (en) 2018-12-05 2020-06-11 Merck Sharp & Dohme Corp. 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
WO2020140959A1 (zh) 2019-01-04 2020-07-09 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020144375A1 (en) 2019-01-11 2020-07-16 Grünenthal GmbH Substituted pyrrolidine amides iii
WO2020151728A1 (zh) 2019-01-25 2020-07-30 江苏恒瑞医药股份有限公司 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用
WO2020261114A1 (en) 2019-06-27 2020-12-30 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
CN112300051A (zh) 2019-07-31 2021-02-02 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN112300069A (zh) 2019-07-31 2021-02-02 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN112390745A (zh) 2019-08-19 2021-02-23 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
WO2021032074A1 (zh) 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CN112441969A (zh) 2019-08-30 2021-03-05 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN112479996A (zh) 2019-09-12 2021-03-12 上海济煜医药科技有限公司 吡啶氮氧化合物及其制备方法和用途
WO2021047622A1 (zh) 2019-09-12 2021-03-18 上海济煜医药科技有限公司 吡啶氮氧化合物及其制备方法和用途
CN111217776A (zh) 2020-01-19 2020-06-02 中国人民解放军军事科学院军事医学研究院 含苯并杂环结构的酰胺衍生物、组合物和应用
WO2021252820A1 (en) 2020-06-10 2021-12-16 Amgen Inc. Cyclobutyl dihydroquinoline sulfonamide compounds
WO2021252822A1 (en) 2020-06-10 2021-12-16 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
WO2021252818A1 (en) 2020-06-10 2021-12-16 Amgen Inc. Cyclopropyl dihydroquinoline sulfonamide compounds
WO2021257420A1 (en) 2020-06-17 2021-12-23 Merck Sharp & Dohme Corp. 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors
WO2021257490A1 (en) 2020-06-17 2021-12-23 Merck Sharp & Dohme Corp. 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
WO2021257418A1 (en) 2020-06-17 2021-12-23 Merck Sharp & Dohme Corp. 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors
WO2022036297A1 (en) 2020-08-14 2022-02-17 Siteone Therapeutics, Inc. Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
CN111808019A (zh) 2020-09-08 2020-10-23 上海济煜医药科技有限公司 一种并环化合物及其应用
CN114591293A (zh) 2020-12-07 2022-06-07 成都康弘药业集团股份有限公司 作为Nav1.8抑制剂的并环化合物及其用途
CN112225695A (zh) 2020-12-15 2021-01-15 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途
CN112457294A (zh) 2021-01-27 2021-03-09 上海济煜医药科技有限公司 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途
WO2022235558A1 (en) 2021-05-07 2022-11-10 Merck Sharp & Dohme Llc Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
WO2022235859A1 (en) 2021-05-07 2022-11-10 Merck Sharp & Dohme Llc Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
WO2022263498A1 (en) 2021-06-15 2022-12-22 Grünenthal GmbH Substituted pyrazole amides

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
"March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS
"The Merck Manual", 2011, MERCK SHARP & DOHME CORP
AKOPIAN, A.N.L. SIVILOTTIJ.N. WOOD: "A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons", NATURE, vol. 379, no. 6562, 1996, pages 257 - 62, XP000605462, DOI: 10.1038/379257a0
BLACK, J.A. ET AL.: "Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas", ANN. NEUROL., vol. 64, no. 6, 2008, pages 644 - 53, XP009143330, DOI: 10.1002/ana.21527
BLAIR, N.T.B.P. BEAN: "Roles of tetrodotoxin (TTX)-sensitive Na+ current, TTX-resistant Na+ current, and Ca2+ current in the action potentials of nociceptive sensory neurons", J. NEUROSCI., vol. 22, no. 23, 2002, pages 10277 - 90
CATTERALL, W. A.GOLDIN, A. L.WAXMAN, S. G.: "International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels", PHARMACOL. REV., vol. 57, no. 4, 2005, pages 397, XP055213863, DOI: 10.1124/pr.57.4.4
CHAHINE, M.CHATCLICR, A.BABICH, 0.KRUPP, J. J.: "Voltage-gated sodium channels in neurological disorders", CNSNEUROL. DISORD. DRUG TARGETS, vol. 7, no. 2, 2008, pages 144 - 58
CHOI, J.S.S.G. WAXMAN: "Physiological interactions between Navl.7 and Na 1.8 sodium channels: a computer simulation study", J. NEUROPHYSIOL., vol. 106, no. 6, pages 3173 - 84
COWARD, K. ET AL.: "Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states", PAIN, vol. 85, no. 1-2, 2000, pages 41 - 50
DIELEMAN, J.P. ET AL.: "Incidence rates and treatment of neuropathic pain conditions in the general population", PAIN, vol. 137, no. 3, 2008, pages 681 - 8, XP022853979, DOI: 10.1016/j.pain.2008.03.002
DONG, X.W. ET AL.: "Small interfering RNA-mediated selective knockdown of Na 1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats", NEUROSCIENCE, vol. 146, no. 2, 2007, pages 812 - 21, XP022061734, DOI: 10.1016/j.neuroscience.2007.01.054
E. W. MARTIN: "Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING CO.
ENGLAND, S.: "Voltage-gated sodium channels: the search for subtypeselective analgesics", EXPERT OPIN. INVESTIG. DRUGS, vol. 17, no. 12, 2008, pages 1849 - 64
HUANG, H.L. ET AL.: "Proteomic profiling of neuromas reveals alterations in protein composition and local protein synthesis in hyper-excitable nerves", MOL. PAIN, vol. 4, 2008, pages 33, XP021045080, DOI: 10.1186/1744-8069-4-33
JARVIS, M.F. ET AL.: "A-803467, a potent and selective Na 1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat", PROC. NATL. ACAD. SCI. USA, vol. 104, no. 20, 2007, pages 8520 - 5, XP055030736, DOI: 10.1073/pnas.0611364104
JOSHI, S.K. ET AL.: "Involvement of the TTX-resistant sodium channel Na 1.8 in inflammatory and neuropathic, but not post-operative, pain states", PAIN, vol. 123, no. 1-2, 2006, pages 75 - 82, XP025024615, DOI: 10.1016/j.pain.2006.02.011
KRAFTE ET AL: "Sodium channels and nociception: recent concepts and therapeutic opportunities", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 8, no. 1, 26 October 2007 (2007-10-26), pages 50 - 56, XP022450582, ISSN: 1471-4892, DOI: 10.1016/J.COPH.2007.09.007 *
KRAFTE, D. S.BANNON, A. W.: "Sodium channels and nociception: recent concepts and therapeutic opportunities", CURR. OPIN. PHARMACOL., vol. 8, no. 1, 2008, pages 50 - 56, XP002540499, DOI: 10.1016/j.coph.2007.09.007
LAI, J. ET AL.: "Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, Nav1.8", PAIN, vol. 95, no. 1-2, 2002, pages 143 - 52, XP002374879, DOI: 10.1016/S0304-3959(01)00391-8
QIU, F. ET AL.: "Increased expression of tetrodotoxin-resistant sodium channels Nav18 and Navl.9 within dorsal root ganglia in a rat model of bone cancer pain", NEUROSCI. LETT., vol. 512, no. 2, pages 61 - 6, XP028903612, DOI: 10.1016/j.neulet.2012.01.069
RENGANATHAN, M., T.R. CUMMINS, S.G. WAXMAN: "Contribution of Na(v) 1.8 sodium channels to action potential electrogenesis in DRG neurons", J. NEUROPHYSIOL., vol. 86, no. 2, 2001, pages 629 - 40
ROZA, C. ET AL.: "The tetrodotoxin-resistant Na- channel Navl.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice", J. PHYSIOL., vol. 550, 2003, pages 921 - 6
ROZA, C. ET AL.: "The tetrodotoxin-resistant Na+ channel Na 1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice", J. PHYSIOL., vol. 550, 2003, pages 921 - 6
RUANGSRI, S. ET AL.: "Relationship of axonal voltage-gated sodium channel 1.8 (Na 1.8) mRNA accumulation to sciatic nerve injury-induced painful neuropathy in rats", J. BIOL. CHEM., vol. 286, no. 46, pages 39836 - 47, XP055624203, DOI: 10.1074/jbc.M111.261701
RUSH, A.M. ET AL.: "A single sodium channel mutation produces hyper- or hypo excitability in different types of neurons", PROC. NATL. ACAD. SCI. USA, vol. 103, no. 21, 2006, pages 8245 - 50
RUSH, A.M.T.R. CUMMINS: "Painful Research: Identification of a Small-Molecule Inhibitor that Selectively Targets Navl.8 Sodium Channels", MOL. INTERV., vol. 7, no. 4, 2007, pages 192 - 5, XP009165204, DOI: 10.1124/mi.7.4.4
S. L. HARBESONR. D. TUNG: "Deuterium In Drug Discovery and Development", ANN. REP. MED. CHEM., vol. 46, 2011, pages 403 - 417
S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
SODERPALM, B.: "Anticonvulsants: aspects of their mechanisms of action", EUR. J. PAIN 6 SUPPL. A, 2002, pages 3 - 9
STRICKLAND, I.T. ET AL.: "Changes in the expression of Na 1.7, Na 1.8 and Na 1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain", EUR. J. PAIN, vol. 12, no. 5, 2008, XP022632366, DOI: 10.1016/j.ejpain.2007.09.001
SUN, W. ET AL.: "Reduced conduction failure of the main axon of polymodal nociceptive C-fibers contributes to painful diabetic neuropathy in rats", BRAIN, vol. 135, pages 359 - 75
T.G.M. WUTS ET AL.: "Greene 's Protective Groups in Organic Synthesis", 2006
THOMAS SORRELL: "Handbook of Chemistry and Physics", 1999, UNIVERSITY SCIENCE BOOKS
V.S. SHIRLEYC.M. LEDERER: "Isotopes Project", January 1980, LAWRENCE BERKELEY LABORATORY, article "Table of Nuclides"
V.S. SHIRLEYC.M. LEDERER: "Nuclear Science Division", January 1980, LAWRENCE BERKELEY LABORATORY, article "Isotopes Project"
WANG, G. K.MITCHELL, J.WANG, S. Y.: "Block of persistent late Na+ currents by antidepressant sertraline and paroxetine", J. MEMBR. BIOL., vol. 222, no. 2, 2008, pages 79 - 90, XP019622596
YIANGOU, Y. ET AL.: "SNS/PN3 and SNS2/NaN sodium channel-like immunoreactivity in human adult and neonate injured sensory nerves", FEBSLETT, vol. 467, no. 2-3, 2000, pages 249 - 52, XP004260962, DOI: 10.1016/S0014-5793(00)01166-2

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025090511A1 (en) * 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025098515A1 (en) * 2023-11-10 2025-05-15 Danatlas Pharmaceuticals Co., Ltd. Heterocyclic derivatives, compositions and uses thereof
WO2025240895A1 (en) * 2024-05-17 2025-11-20 Siteone Therapeutics, Inc. SUBSTITUTED CYCLOALKYL AND HETEROCYCLOALKYL INHIBITORS OF NAv1.8 FOR THE TREATMENT OF PAIN
WO2025256572A1 (zh) * 2024-06-13 2025-12-18 海思科医药集团股份有限公司 一种Nav1.8抑制剂及其在医药上的应用
WO2026001999A1 (zh) * 2024-06-25 2026-01-02 江苏恒瑞医药股份有限公司 芳香环类化合物、其制备方法及其在医药上的应用
WO2026008013A1 (zh) * 2024-07-03 2026-01-08 江苏恒瑞医药股份有限公司 氧代杂芳基类化合物、其制备方法及其在医药上的应用
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain
WO2026057012A1 (zh) * 2024-09-12 2026-03-19 江苏恒瑞医药股份有限公司 芳香环类化合物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
UY40234A (es) 2023-11-15
US20230373925A1 (en) 2023-11-23
US12503439B2 (en) 2025-12-23
PE20251179A1 (es) 2025-04-23
WO2023205463A8 (en) 2024-03-28
CN119677737A (zh) 2025-03-21
GEAP202516632A (en) 2025-02-25
TW202404969A (zh) 2024-02-01
EP4511116A1 (en) 2025-02-26
JP2025513455A (ja) 2025-04-24
CL2024003232A1 (es) 2025-06-13
DOP2024000209A (es) 2025-04-08
IL316462A (en) 2024-12-01
AU2023256603A1 (en) 2024-11-07
MX2024013020A (es) 2024-11-08
KR20250005373A (ko) 2025-01-09
AR129104A1 (es) 2024-07-17
CO2024015820A2 (es) 2024-11-28
CR20240513A (es) 2025-04-30
JOP20240235A1 (ar) 2024-10-22

Similar Documents

Publication Publication Date Title
EP4347031B1 (en) N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US20240294512A1 (en) Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
US20240400544A1 (en) N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
US12440481B2 (en) Esters and carbamates as modulators of sodium channels
US12503439B2 (en) Heteroaryl compounds for the treatment of pain
WO2023205778A1 (en) Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) Heteroaryl compounds for the treatment of pain
AU2024367861A1 (en) Heteroaryl compounds for the treatment of pain
WO2025090480A1 (en) Heteroaryl compounds for the treatment of pain
US20260001877A1 (en) Heteroaryl compounds for the treatment of pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23724521

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2024562079

Country of ref document: JP

Ref document number: 316462

Country of ref document: IL

Ref document number: 2401006954

Country of ref document: TH

Ref document number: 815657

Country of ref document: NZ

Ref document number: AU2023256603

Country of ref document: AU

Ref document number: 002287-2024

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 12024552532

Country of ref document: PH

Ref document number: MX/A/2024/013020

Country of ref document: MX

Ref document number: P2024-02809

Country of ref document: AE

Ref document number: 140350140003005096

Country of ref document: IR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024021783

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2023256603

Country of ref document: AU

Date of ref document: 20230421

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2024001453

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 16632

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 202417090238

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 202492727

Country of ref document: EA

Ref document number: NC2024/0015820

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20247039041

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020247039041

Country of ref document: KR

Ref document number: 2023724521

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023724521

Country of ref document: EP

Effective date: 20241122

WWP Wipo information: published in national office

Ref document number: NC2024/0015820

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 11202407333Q

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 202380047901.3

Country of ref document: CN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112024021783

Country of ref document: BR

Free format text: APRESENTE UM ESCLARECIMENTO INDICANDO AS MODIFICACOES FEITAS NA PETICAO NO 870240102883 OU, ALTERNATIVAMENTE, COPIA DOS DOCUMENTOS ORIGINAIS COM AS MODIFICACOES MARCADAS CONFORME ART. 57 DA PORTARIA/INPI/NO 14/2024. EXPLIQUE A DIVERGENCIA NO NOME DE UM DOS INVENTORES (DENNIS JAMES HURLEY) QUE CONSTA NA PUBLICACAO INTERNACIONAL WO 2023/205463 E O CONSTANTE DA PETICAO INICIAL. A EXIGENCIA DEVE SER RESPONDIDA EM ATE 60 (SESSENTA) DIAS DE SUA PUBLICACAO E DEVE SER REALIZADA POR MEIO DA PETICAO GRU CODIGO DE SERVICO 207.

WWP Wipo information: published in national office

Ref document number: 202380047901.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 140350140003005096

Country of ref document: IR

ENP Entry into the national phase

Ref document number: 112024021783

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20241021